NeurAxis (NASDAQ:NRXS – Get Free Report) and Medtronic (NYSE:MDT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength ...

In a trial that many are calling landmark, transcatheter aortic valve replacement had better outcomes than surveillance for ...

Minneapolis, Minnesota-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to ...

The Global Transcatheter Cardiac Valve Replacement (THVR) Market, valued at USD 6.54 billion in 2023, is anticipated to grow significantly with a CAGR of 14.8% over the forecast period of 2024 to 2032 ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

Boston Scientific (NYSE:BSX) today announced that a study of its Acurate neo2 aortic valve system missed its primary endpoint ...

The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.

Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in a head-to-head study aimed at bringing the implant to the U.S.—but the company believ | Boston Scientific’s ...

A Chinese study suggested that cold weather may make people more susceptible to myocardial infarction with non-obstructive ...